Phase 3 Trial Tests Infliximab as a Powerful Treatment for Plaque Psoriasis
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
Summary
This completed Phase 3 clinical trial, sponsored by Centocor, investigated whether infliximab — a biologic drug that blocks tumor necrosis factor (TNF), a key inflammatory protein — could safely and effectively treat plaque psoriasis, the most common form of the disease. Psoriasis is a chronic autoimmune condition causing red, scaly skin patches that significantly impair quality of life. Infliximab works by dampening the overactive immune response that drives skin inflammation. As a Phase 3 study, this represented a late-stage, rigorous evaluation of the drug's real-world potential before regulatory consideration. The trial was fully completed, and its results contributed to the broader evidence base supporting anti-TNF therapies in dermatology. This research is particularly relevant given the increasing recognition that chronic inflammation underlies not only autoimmune conditions but also aging and age-related disease.
Detailed Summary
Plaque psoriasis affects roughly 2–3% of the global population and is far more than a cosmetic concern. It is a chronic, immune-mediated inflammatory disease associated with significant comorbidities including cardiovascular disease, metabolic syndrome, and depression — all of which are also key concerns in longevity medicine. Controlling systemic inflammation in psoriasis may therefore have benefits well beyond skin clearance.
This completed Phase 3 clinical trial, sponsored by Centocor (now Janssen), set out to determine whether infliximab — a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α) — was both safe and effective for patients with plaque psoriasis. TNF-α is a central mediator of the inflammatory cascade that drives psoriatic skin lesions, making it a logical therapeutic target.
Phase 3 trials represent the gold standard of clinical evidence, typically enrolling large patient populations across multiple sites to confirm efficacy, monitor adverse events, and compare outcomes against placebo or standard of care. The completion of this trial suggests it generated meaningful data on infliximab's benefit-risk profile in this population.
The implications extend into longevity science. Chronic low-grade inflammation — sometimes called 'inflammaging' — is increasingly understood as a driver of biological aging. Anti-TNF therapies like infliximab that suppress systemic inflammatory burden may, in theory, confer protective effects on cardiovascular and metabolic health over the long term, though this remains an active area of investigation.
Key caveats apply: only the abstract is available, so specific efficacy endpoints, response rates, and safety data cannot be verified here. Additionally, infliximab requires intravenous administration and carries risks including infection susceptibility and rare serious adverse events, which must be weighed carefully in clinical practice. Full published results would be necessary to draw firm conclusions.
Key Findings
- Phase 3 trial completed evaluating infliximab (anti-TNF biologic) for plaque psoriasis safety and efficacy.
- Infliximab targets TNF-α, a central inflammatory mediator implicated in both psoriasis and systemic aging.
- Anti-TNF therapy may address the systemic inflammation underlying psoriasis and its cardiovascular comorbidities.
- Sponsored by Centocor, this trial contributed to the regulatory evidence base for biologic psoriasis treatment.
- Chronic inflammation control in psoriasis may have broader longevity implications beyond skin clearance.
Methodology
This was a Phase 3 randomized clinical trial assessing the safety and efficacy of infliximab in patients diagnosed with psoriasis. Sponsored by Centocor, Inc., the trial has been completed, though full design details including sample size, comparator arms, and primary endpoints are unavailable from the abstract alone. Phase 3 designation indicates a large-scale, controlled trial designed to confirm therapeutic benefit prior to regulatory submission.
Study Limitations
This summary is based on the abstract only, as the full trial data are not openly accessible; specific efficacy rates, dosing regimens, and adverse event profiles cannot be confirmed. The brief abstract provides no details on study design elements such as sample size, control arms, blinding, or follow-up duration. Conclusions about the magnitude of benefit or safety findings must await review of the full published results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.